Beta blocker benefits in asthma reported

9 March 2009

The American Asthma Foundation has announced a research breakthrough  suggesting that, contrary to popular belief, drugs commonly used to  treat high blood pressure may also bring relief to many asthma  sufferers.

Dean Smith, executive director of the AAF, said, "drugs known as beta  blockers have long been used to treat high blood pressure. However, they  have historically been forbidden for patients with asthma, because they  may make the symptoms worse. Now, however, results from a research study  funded by the American Asthma Foundation suggest that, over the long  run, asthma may well improve with low daily doses of beta blockers."

The findings were published January 26 on www.pnas.org, the on-line  edition of Proceedings of the National Academy of Sciences of the USA.  The lead investigator, Richard Bond, and his colleagues demonstrated the  absence of asthma-like symptoms in laboratory mice that do not have the  very receptor that is inhibited by beta blockers. This finding was in  agreement with earlier studies by Dr Bond et al showing that low doses  of beta blockers improved asthma in mice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight